NEX-I isn't just another biotech firm — it's the future. We're pioneering a transformative shift in cancer immunotherapy, unveiling robust solutions – start with our 1st episode, ONCOKINE^®. While conventional treatments often face resistance from evolving cancer cells, our groundbreaking platform identifies and counters this challenge. By understanding the mechanisms of refractory cancers and targeting ONCOKINE^®, NEX-I sets a new standard. We're redefining the battle against cancer by actively inhibiting cancer cell growth and putting an end to metastasis. Experience the next era of cancer therapy with NEX-I.